Global Gene Therapy for Age-related Macular Degeneration Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023

Description:
Macular degeneration is a condition in which, macula, a part of the retina, gets damaged or deteriorated. This condition usually affects individuals who are aged 50 years and above and therefore, it is called age-related macular degeneration (AMD). AMD is the leading cause of vision loss and is directly related to the advancement of age. But smoking also plays a vital role in causing AMD. AMD is characterized by the presence of a blurred area near the center of vision that leads to distorted vision. There are two different types of AMD, including dry (atrophic) AMD (dAMD) and wet (neovascular/exudative) AMD (wAMD). The dAMD is the most common type of AMD and accounts for almost 80%-90% of the overall AMD cases.

Scope of the Report:
This report studies the Gene Therapy for Age-related Macular Degeneration market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Gene Therapy for Age-related Macular Degeneration market by product type and applications/end industries.

It has been observed that age-related macular degeneration (AMD) is one of the major causes for vision loss and is characterized by the formation of a blurred area near the center of vision, a condition that mostly affects the geriatric population. According to the CDC, almost 2 million individuals in the US suffer from AMD and by 2050, this number will reach more than 5 million. This will subsequently demand the need for the development of innovative treatments for AMD, driving the market’s growth.

The market research analysts have predicted that with the introduction of techniques such as fluorescein angiography, the global age-related macular degeneration market will register a CAGR of more than 7% by 2020. With the unavailability of FDA-approved treatment for dry AMD (dAMD) and the treatment of wet AMD (wAMD) involving the need of intravitreal injections for an indefinite period, gene therapy is emerging as the most-efficient approach for the treatment of age-related macular degeneration (AMD).

According to this pipeline analysis report, most of the gene therapy molecules in the pipeline are being developed for wet AMD (wAMD). Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.

The global Gene Therapy for Age-related Macular Degeneration market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.

The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Gene Therapy for Age-related Macular Degeneration.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.

Market Segment by Companies, this report covers
RetroSense Therapeutics
REGENXBIO
AGTC

Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers
Subretinal
Intravitreal
Unspecified

Market Segment by Applications, can be divided into
Monotherapy
Combination Therapy

Contents:
1 Gene Therapy for Age-related Macular Degeneration Market Overview
1.1 Product Overview and Scope of Gene Therapy for Age-related Macular Degeneration
1.2 Classification of Gene Therapy for Age-related Macular Degeneration by Types
1.2.1 Global Gene Therapy for Age-related Macular Degeneration Revenue Comparison by Types (2017-2023)
1.2.2 Global Gene Therapy for Age-related Macular Degeneration Revenue Market Share by Types in 2017
1.2.3 Subretinal
1.2.4 Intravitreal
1.2.5 Unspecified
1.3 Global Gene Therapy for Age-related Macular Degeneration Market by Application
1.3.1 Global Gene Therapy for Age-related Macular Degeneration Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Monotherapy
1.3.3 Combination Therapy
11.3 Monotherapy Revenue Growth (2013-2018)
11.4 Combination Therapy Revenue Growth (2013-2018)
12 Global Gene Therapy for Age-related Macular Degeneration Market Size Forecast (2018-2023)
12.1 Global Gene Therapy for Age-related Macular Degeneration Market Size Forecast (2018-2023)
12.2 Global Gene Therapy for Age-related Macular Degeneration Market Forecast by Regions (2018-2023)
12.3 North America Gene Therapy for Age-related Macular Degeneration Revenue Market Forecast (2018-2023)
12.4 Europe Gene Therapy for Age-related Macular Degeneration Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Gene Therapy for Age-related Macular Degeneration Revenue Market Forecast (2018-2023)
12.6 South America Gene Therapy for Age-related Macular Degeneration Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Gene Therapy for Age-related Macular Degeneration Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source